Download Files:
ROCK Inhibitor, Y-27632 (dihydrochloride)
$55 – $2,650
Products Details
Product Description
– Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects[1][2][3][4].
Web ID
– HY-10583
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C14H23Cl2N3O
Citations
– Am J Physiol Cell Physiol. 2023 May 1.|Biochem Biophys Res Commun. 2021 Mar 18;552:142-149.|Biomaterials. 2021, 120684.|Biomolecules. 2023, 13(1), 69.|bioRxiv. 2023 Feb 16.|bioRxiv. April 21, 2022.|Breast Cancer Res. 2021 Aug 3;23(1):82.|Cancers (Basel). 2022 May 17;14(10):2463.|Cancers (Basel). 2023, 15(3), 931.|cell analysis. 2020 Aug.|Cell Mol Gastroenterol Hepatol. 2022 Nov 24;S2352-345X(22)00238-7.|Cell Stem Cell. 2020 Jul 2;27(1):125-136.e7. |Cell Stem Cell. 2020 Jun 4;26(6):845-861.e12. |Cell Stem Cell. 2022 Jul 7;29(7):1102-1118.e8.|Cell Stem Cell. 2022 May 5;29(5):776-794.e13.|Cell Stem Cell. 2022 Oct 6;29(10):1475-1490.e6.|Curr Protoc Cell Biol. 2018 Dec;81(1):e62.|Curr Protoc. 2023 Oct;3(10):e915.|Food Chem Toxicol. 2020 Jan;135:111015.|Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):1. |iScience. 2022 Dec 26;26(1):105898.|J Adv Res. 2023 Oct 6:S2090-1232(23)00299-0.|J Biol Chem. 2022 Aug 12;102374.|J Environ Sci. 2023 Feb 23.|J Exp Clin Cancer Res. 2018 Jun 28;37(1):128. |J Hazard Mater. 2020 Jul 5;393:122440.|J Hazard Mater. 2021 Apr 5;407:124387.|J Hazard Mater. 2021 Jan 5;401:123341.|JCI Insight. 2023 Nov 8;8(21):e167874.|Life Sci. 2023 Jan 18;316:121404.|Microvasc Res. 2023 Sep 28:151:104611.|Nat Commun. 2023 Nov 27;14(1):7783.|Nat Protoc. 2021 Jan;16(1):352-382.|Nat Protoc. 2023 Feb 15.|Nature. 2022 Jan;601(7894):600-605.|Nature. 2022 Nov;611(7936):603-613.|Nutrients. 2023 Feb 9;15(4):887.|Patent. US20180263995A1.|Patent. US20220062272A1.|Research Square Preprint. 2020 Aug 20;rs.3.rs-62758.|Sci Adv. 2021 Sep 17;7(38):eabb5933.|Science. 2020 Dec 4;370(6521):eaay2002.|STAR Protoc. 16 December 2022, 101786.|STAR Protoc. 2022 Sep 26;3(4):101720.|STAR Protoc. 2023 Jul 9;4(3):102431.|STAR Protoc. 2023 Nov 16;4(4):102683.|Stem Cell Res. October 2021, 102544.|ACS Appl Mater Interfaces. 2022 May 11.|Acs Biomater Sci Eng. 2022 Mar 1.|Acs Biomater Sci Eng. 2023 Jan 20.|Acta Pharm Sin B. 2023 May 16.|Adv Healthc Mater. 2021 Feb 15;e2002103.|Adv Sci (Weinh). 2020 Jun 17;7(15):1903583.|Adv Sci (Weinh). 2023 Nov 29:e2303088.|Anal Chem. 2017 Oct 17;89(20):10841-10849.|Bioact Mater. 14 August 2022.|Bioact Mater. 2021 Jun 1.|Bioact Mater. 2023 Aug.|Biochem Biophys Rep. September 2022, 101299.|Biochem Biophys Res Commun. 2019 Aug 20;516(2):571-577.|Biochem Biophys Res Commun. 2019 Oct 29;519(1):134-140.|Biochem Biophys Res Commun. 2023|Bioengineered. 2022 Apr;13(4):8747-8758.|Bioengineering (Basel). 2020 Dec 18;7(4):164.|Biology (Basel). 2023, 12(6), 888.|Biomaterials. 2020 May;240:119849.|Biomaterials. 2020 Nov;258:120284.|Biomed Pharmacother. September 2022, 113465.|Biomed Res Int. 2021 May 15.|bioRxiv. 2020 Aug.|bioRxiv. 2020 Mar.|bioRxiv. 2023 Feb 24.|bioRxiv. 2023 Jul 1.|bioRxiv. 2023 Jun 22.|bioRxiv. 2023 Jun 28.|bioRxiv. 2023 Mar 1.|bioRxiv. January 16, 2022.|Biosci Biotechnol Biochem. 2021 Jul 23;zbab136.|BMC Cancer. 2023 Jun 22;23(1):577.|BMC Urol. 2021 Jan 6;21(1):5.|Bone Res. 2022 Jan 3;10(1):1.|Brain Res. 15 December 2021, 147684.|Can Respir J. 10 Oct 2022.|Cancer Cell. 2023 Jun 12;41(6):1103-1117.e12.|Cancer Lett. 2019 Apr 28;448:117-127.|Cancer Res. 2022 Dec 8;CAN-22-2370.|Cancers (Basel). 2021, 13(13), 3282.|Cell Biochem Biophys. 2023 Oct 6.|Cell Death Dis. 2022 Aug 24;13(8):730.|Cell Death Dis. 2023 Apr 20;14(4):280.|Cell Death Discov. 2023 Jan 25;9(1):32.|Cell Discov. 2021 Apr 19;7(1):25.|Cell Discov. 2022 Apr 19;8(1):35.|Cell Prolif. 2022 Aug 3;e13320.|Cell Prolif. 2022 Mar 11;e13209.|Cell Regen. 2020 Sep 3;9(1):15.|Cell Rep Med. 2023 Jan 10;100911.|Cell Rep. 2023 May 2;42(5):112445.|Cell Rep. 2023 Oct 5;42(10):113213.|Cell Rep. 2019 Jan 8;26(2):407-414.e5.|Cell Res. 2023 Jul 17.|Cell Stem Cell. 2020 Oct 1;27(4):646-662.e7. |Cell Stem Cell. 2022 Sep 1;29(9):1346-1365.e10.|Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.|Chem Biol Interact. 17 August 2021, 109625.|Chem Eng J. 1 January 2023, 138737.|Circ Res. 2020 Oct 9;127(9):1182-1194.|Clin Mol Hepatol. 2023 Feb 20.|Compos Part B-Eng. 2023 Apr 6, 110711.|Connect Tissue Res. 2022 Jan 12;1-10.|EMBO Mol Med. 2022 Dec 13;e16373.|Environ Pollut. 2020 Jun;261:114153.|Environ Toxicol Pharmacol. 2023 Oct 20:104301.|Eur J Immunol. 2022 Aug;52(8):1308-1320.|Exp Mol Med. 2021 Sep 21.|Exp Mol Med. 2023 Jun 19.|Exp Ther Med. 2021 Feb 3.|F1000Research. 03 Aug 2022.|FASEB J. 03 October 2022.|Front Cell Dev Biol. 2021 Jun 24;9:670825.|Front Med. 2021 Sep 23;8:746298.|Front Physiol. 2020 Jun 30;11:669.|Gut Microbes. 2022, 14(1): 2139978.|Harvard Medical School LINCS LIBRARY|Hum Mol Genet. 2022 Aug 10;ddac190.|Immunity. 2022 Mar 15;S1074-7613(22)00124-8.|Int J Biol Sci. 2022 Aug 29;18(14):5459-5474.|Int J Mol Sci. 2022, 23(23), 14637|Int J Mol Sci. 2023 Oct 31, 24(21), 15804.|iScience. 19 October 2021, 103303.|iScience. 2023 Aug 26.|J Biol Chem. 2023 Oct 19:105361.|J Biosci Bioeng. 2020 Dec 23;S1389-1723(20)30432-1.|J Bone Oncol. October 2021, 100391.|J Cell Mol Med. 2020 Jul;24(14):8179-8193.|J Clin Invest. 2022 Jan 25;e154993.|J Clin Med. 2019 Oct 21;8(10):1751.|J Med Chem. 2019 Jul 11;62(13):6083-6101.|J Neurosci. 2021 Jan 20;41(3):392-407.|J Transl Med. 2023 Oct 10;21(1):711.|J Virol. 2021 Feb 24;95(10):e02436-20.|J Virol. 2023 Apr 27;e0177022.|Life Sci. 2020 Apr 1;246:117419.|Life. 2021, 11(8), 789.|Mat Sci Eng C-Mater. 2021, 111939.|Med Sci Monit. 2018 May 27;24:3514-3523. |Methods Mol Biol. 2022 Dec 15.|Methods Mol Biol. 2023;2683:53-68.|Mol Cell. 2021 Jul 1;81(13):2736-2751.e8.|Mol Med. 2023 Oct 20;29(1):139.|Nat Cell Biol. 2022 Jun;24(6):858-871.|Nat Commun. 2022 Apr 19;13(1):2028.|Nat Commun. 2022 Jun 1;13(1):3060.|Nat Commun. 2022 Sep 6;13(1):5237.|Nat Commun. 2023 Apr 6;14(1):1912.|Nat Commun. 2023 Aug 8;14(1):4779.|Neurotherapeutics. 2021 Jan 21.|NPJ Regen Med. 2022 Jun 16;7(1):31.|Nutr Metab. 2020 Oct 26;17:91.|Oncogene. 2023 Aug 31.|Oncol Rep. 2020 Sep;44(3):1266-1274.|Oncotarget. 2017 Jul 31;8(47):82506-82530.|Patent. US20210284970A1.|Patent. US20220177852A1.|Patent. US20220267735A1.|Pharmacol Res. 2022 Dec 16;187:106615.|Protein Cell. 2021 Feb;12(2):107-127.|Research (Wash D C). 2023 Oct 24.|Research Square Preprint. 2021 Jan.|Research Square Preprint. 2021 May.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2023 May 30.|Respir Res. 2022 Mar 25;23(1):70.|Sci Adv. 2023 Oct 27;9(43):eadg6686.|Sci Rep. 2017 Dec 19;7(1):17770.|Sci Rep. 2021 Dec 7;11(1):23564.|Sci Rep. 2019 Dec 17;9(1):19301. |Sci Total Environ. 2020 Jul 10;725:138433.|Sci Total Environ. 2022 May 18;838(Pt 2):155811.|Small. 2021 Jun 8;e2100546.|Small. 2021 Nov 2;e2104773.|SSRN. 2023 Feb 6.|STAR Protoc. 2021 Nov 5;2(4):100881.|STAR Protoc. 2023 Feb 3;4(1):102092.|Stem Cell Res Ther. 2019 May 31;10(1):155.|Stem Cell Res. 2021, 102157.|Stem Cell Res. 2021, 102217.|Stem Cell Res. 2022 Sep 15;64:102916.|Theranostics. 2022 Mar 21;12(6):2908-2927.|Theranostics. 2022 Mar 28;12(7):3131-3149.|Theranostics. 2022; 12(17): 7250-7266|Theranostics. 2023 May 27;13(10):3290-3309.|Toxicology. 2020 Oct;443:152573.|Vaccines. 2023 May 17, 11(5), 993.|Virology. 2023 May 3;583:45-51.
References
– [1]Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34(4):529-36.|[2]Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155(1):44-51.|[3]Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells. Chin Med J (Engl). 2012 Sep;125(18):3332-5.|[4]Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.
CAS Number
– 129830-38-2
Molecular Weight
– 320.26
Compound Purity
– 99.98
SMILES
– O=C([C@@H]1CC[C@]([C@H](N)C)([H])CC1)NC2=CC=NC=C2.[H]Cl.[H]Cl
Clinical Information
– No Development Reported
Research Area
– Cancer; Neurological Disease
Solubility
– DMSO : 33.33 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
Target
– ROCK
Isoform
– ROCK1;ROCK2
Pathway
– Cell Cycle/DNA Damage;Cytoskeleton;Stem Cell/Wnt;TGF-beta/Smad
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
